VEGFA and nasopharyngeal carcinoma: Lenvatinib significantly inhibited the migration and invasion of nasopharyngeal carcinoma HK-1 cells, as well as the expression of tumor angiogenesis-related proteins, such as VEGF and PDGF 11.